Literature DB >> 180868

Increased resistance to virus infections of mice inoculated with BCG (Bacillus calmette-guérin).

F Floc'h, G H Werner.   

Abstract

CD-1 or OF-1 mice were inoculated intravenously with 1 mg per mouse (i.e. about 10(6) live bacilli) of Pasteur Institute BCG and challenged 15 to 31 days later with the following viruses introduced by various routes: encephalomyocarditis, murine hepatitis, type 1 and 2 herpes simplex, foot-and-mouth disease and A0 and A2 influenza viruses. In most cases, BCG-inoculated mice exhibited a significantly higher resistance to these lethal infections than control mice (overall survival in control: 18%; in BCG-inoculated mice: 41%). Enhancement of resistance by BCG was especially marked in infections with encephalomyocarditis, herpes simplex type 1 and influenza A2 viruses. Intercurrent infection of BCG-inoculated mice with non lethal doses of viruses did not abrogate their resistance towards subsequent challenge with lethal doses of an unrelated virus. The possible mechanisms of this enhancing effect of BCG on host's resistance are discussed in the light of the known effects of this immunostimulating agent on the various facets of the immune response and of the respective roles the latter play in the defence against virus infections.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 180868

Source DB:  PubMed          Journal:  Ann Immunol (Paris)        ISSN: 0300-4910


  13 in total

1.  Effect of Mycobacterium tuberculosis BCG infection on the resistance of mice to ectromelia virus infection: participation of interferon in enhanced resistance.

Authors:  T Suenaga; T Okuyama; I Yoshida; M Azuma
Journal:  Infect Immun       Date:  1978-04       Impact factor: 3.441

2.  Mechanisms of enhanced resistance of Mycobacterium bovis BCG-treated mice to ectromelia virus infection.

Authors:  T Sakuma; T Suenaga; I Yoshida; M Azuma
Journal:  Infect Immun       Date:  1983-11       Impact factor: 3.441

3.  Enhancement of bronchoalveolar cell recovery and stimulation of alveolar macrophage chemiluminescence and resistance to influenza virus after treatment with RU 41821 aerosol.

Authors:  A Rudent; F Michel; C Labarre; A M Quero; R Zalisz; P Smets
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

4.  The enhancement of tetrathyridial proliferation of Mesocestoides corti in mice by B.C.G.

Authors:  R C Thompson; W J Penhale
Journal:  Z Parasitenkd       Date:  1978-07-04

5.  Considering BCG vaccination to reduce the impact of COVID-19.

Authors:  Nigel Curtis; Annie Sparrow; Tedros A Ghebreyesus; Mihai G Netea
Journal:  Lancet       Date:  2020-04-30       Impact factor: 79.321

Review 6.  Gut Microbiota Dysbiosis-Immune Hyperresponse-Inflammation Triad in Coronavirus Disease 2019 (COVID-19): Impact of Pharmacological and Nutraceutical Approaches.

Authors:  Carolina Ferreira; Sofia D Viana; Flávio Reis
Journal:  Microorganisms       Date:  2020-10-01

Review 7.  BCG Vaccine-Induced Trained Immunity and COVID-19: Protective or Bystander?

Authors:  Khalid Muhammad; Helal F Hetta; Gopala Koneru; Gaber El-Saber Batiha; Abdelazeem M Algammal; Mahmoud Mabrok; Sara Magdy; Shrouk Sayed; Mai E AbuElmagd; Reham Elnemr; Mahmoud M Saad; Noura H Abd Ellah; Amal Hosni
Journal:  Infect Drug Resist       Date:  2021-03-23       Impact factor: 4.003

Review 8.  Genetic gateways to COVID-19 infection: Implications for risk, severity, and outcomes.

Authors:  Monojit Debnath; Moinak Banerjee; Michael Berk
Journal:  FASEB J       Date:  2020-06-11       Impact factor: 5.834

Review 9.  Hidden in plain sight: The effects of BCG vaccination in the COVID-19 pandemic.

Authors:  Eman A Toraih; Jessica A Sedhom; Titilope M Dokunmu; Mohammad H Hussein; Emmanuelle M L Ruiz; Kunnimalaiyaan Muthusamy; Mourad Zerfaoui; Emad Kandil
Journal:  J Med Virol       Date:  2020-12-17       Impact factor: 20.693

Review 10.  The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development.

Authors:  Sana O Alturki; Sawsan O Alturki; Jennifer Connors; Gina Cusimano; Michele A Kutzler; Abdullah M Izmirly; Elias K Haddad
Journal:  Front Immunol       Date:  2020-08-19       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.